Online inquiry

IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8572MR)

This product GTTS-WQ8572MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD47 gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers(CRC), Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001777.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 961
UniProt ID Q08722
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ8572MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ846MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-155
GTTS-WQ14572MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ3174MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AR-101
GTTS-WQ8392MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HS006
GTTS-WQ7373MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ12728MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ10006MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KRN-23
GTTS-WQ14264MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG-7116
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW